About Harbour BioMed
Harbour BioMed is a company based in Shanghai (China) founded in 2016 by Jingsong Wang.. Harbour BioMed has raised $312.8 million across 5 funding rounds from investors including Sage Group, SK and Orbimed. Harbour BioMed has completed 1 acquisition, including Harbour Antibodies. Harbour BioMed operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Shanghai, China
- Founders Jingsong Wang
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$312.8 M (USD)
in 5 rounds
-
Latest Funding Round
$102.8 M (USD), Series C
Jul 09, 2020
-
Investors
Sage Group
& 18 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Harbour BioMed
Harbour BioMed has successfully raised a total of $312.8M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $102.8 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series C — $102.8M
-
First Round
First Round
(01 Dec 2016)
- Investors Count 19
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2020 | Amount | Series C - Harbour BioMed | Valuation | Hudson Bay Capital | |
| Mar, 2020 | Amount | Series B - Harbour BioMed | Valuation | ZSVC , Zhejiang University | |
| Aug, 2018 | Amount | Series B - Harbour BioMed | Valuation | GIC |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Harbour BioMed
Harbour BioMed has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Sage Group, SK and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Equity investment management is provided by Zhejiang Venture Capital.
|
Founded Year | Domain | Location | |
|
Venture Capital firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Sovereign wealth is managed and private equity investments are facilitated.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Harbour BioMed
Harbour BioMed has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Harbour Antibodies. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Production of antibodies and VH (heavy chain with one variable) domains for therapy
|
2006 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Harbour BioMed
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Harbour Biomed Comparisons
Competitors of Harbour BioMed
Harbour BioMed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Harbour Biomed
Frequently Asked Questions about Harbour BioMed
When was Harbour BioMed founded?
Harbour BioMed was founded in 2016.
Where is Harbour BioMed located?
Harbour BioMed is headquartered in Shanghai, China.
Who is the current CEO of Harbour BioMed?
Jingsong Wang is the current CEO of Harbour BioMed. They have also founded this company.
Is Harbour BioMed a funded company?
Harbour BioMed is a funded company, having raised a total of $312.8M across 5 funding rounds to date. The company's 1st funding round was a Series B of $85M, raised on Dec 01, 2016.
What does Harbour BioMed do?
Developer of antibody therapeutics in immunology and oncology disease. The products Batoclimab for the treatment of autoimmune diseases, Tanfanercept for the treatment of dry eye disease, HBM4003, HBM9022, to prevent and treat COVID-19, and various candidates for treating solid tumors, myeloma, and cancer. The company has a Harbour Mice, HBICE, and single-cell technology platform to generate fully human monoclonal antibodies.
Who are the top competitors of Harbour BioMed?
Harbour BioMed's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
How many acquisitions has Harbour BioMed made?
Harbour BioMed has made 1 acquisition, including Harbour Antibodies.
Who are Harbour BioMed's investors?
Harbour BioMed has 19 investors. Key investors include Sage Group, SK, Orbimed, Country Garden, and Advantech.